Home/Investors/Third Rock Ventures

Third Rock Ventures

Biotech Investor · 12 portfolio companies

Portfolio

12

Combined Value

$32.1B

Focus Areas

12

Top Stage

preclinical

Investment Focus

Oncology Immunology Inflammation Autoimmune Diseases Allergic Diseases Dermatology Aesthetic Medicine Genetic Disease Neuroscience Metabolic Cardiovascular Hepatology

Portfolio Companies

Company	Stage	Valuation	Focus
REVOLUTION Medicines	Phase 2	$30.4B	Oncology
Monte Rosa Therapeutics	Phase 2	$1.7B	Oncology, Immunology
ARTBIO	Phase 2	—	Oncology
Perimeter Systems, Inc.	preclinical	—	Oncology
Merida Biosciences	Pre-clinical	—	Autoimmune Diseases, Allergic Diseases
Follica	Phase 2	—	Dermatology, Aesthetic Medicine
Terremoto Biosciences	Phase 1	—	Oncology, Genetic Disease
Flare Therapeutics	preclinical	—	Oncology, Neuroscience
Marea Therapeutics	phase-2	—	Metabolic, Cardiovascular
Diagonal Therapeutics	preclinical	—	Cardiovascular, Immunology
Corxel Pharmaceuticals	preclinical	—	Oncology, Immunology
MOMA Therapeutics	preclinical	—	Oncology

Frequent Co-Investors

Versant Ventures2 shared ARCH Venture Partners2 shared Boxer Capital2 shared OrbiMed1 shared Public market investors1 shared Cormorant Asset Management1 shared The Column Group1 shared Sofinnova Investments1 shared